Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer

In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease control in a subset of patients. The IMvigor130 trial reveals more favorable effects with atezolizumab combined with gemcitabine and cisplatin (GemCis) versus gemcitabine and carboplatin (GemCarbo). This stu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports. Medicine 2024-02, Vol.5 (2), p.101393-101393, Article 101393
Hauptverfasser:	Galsky, Matthew D., Guan, Xiangnan, Rishipathak, Deepali, Rapaport, Aaron S., Shehata, Hesham M., Banchereau, Romain, Yuen, Kobe, Varfolomeev, Eugene, Hu, Ruozhen, Han, Chia-Jung, Li, Haocheng, Liang, Yuxin, Vucic, Domagoj, Wang, Li, Zhu, Jun, Yu, Haocheng, Herbst, Rebecca H., Hajaj, Emma, Kiner, Evgeny, Bamias, Aristotelis, De Santis, Maria, Davis, Ian D., Arranz, José Ángel, Kikuchi, Eiji, Bernhard, Sandrine, Williams, Patrick, Lee, Chooi, Mellman, Ira, Sanjabi, Shomyseh, Johnston, Robert, Black, Peter C., Grande, Enrique, Mariathasan, Sanjeev
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized bladder cancer carboplatin Carboplatin - therapeutic use Carcinoma, Transitional Cell - chemically induced Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology chemotherapy cisplatin Cisplatin - therapeutic use Deoxycytidine - therapeutic use Gemcitabine Humans immune checkpoint blockade immunogenic cell death PD-1 blockade PD-L1 blockade single cell RNA sequencing Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urologic Neoplasms - chemically induced Urologic Neoplasms - drug therapy Urologic Neoplasms - pathology urothelial cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!